细胞外囊泡在心房颤动发病中的作用

doi:10.16352/j.issn.1001-6325.2022.04.008

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (4): 671-674.doi: 10.16352/j.issn.1001-6325.2022.04.008

细胞外囊泡在心房颤动发病中的作用

何丹, 阮中宝^*

泰州市人民医院心血管内科, 江苏泰州 225300

收稿日期:2021-07-31 修回日期:2021-11-08 出版日期:2022-04-05 发布日期:2022-04-01
通讯作者: * tzcardiac@163.com
基金资助:
江苏省自然科学基金(BK20161370);江苏省医学创新团队(CXTDB2017015)

Extracellular vesicles in the pathogenesis of atrial fibrillation

HE Dan, RUAN Zhong-bao^*

Department of Cardiology, Taizhou People's Hospital, Taizhou 225300, China

Received:2021-07-31 Revised:2021-11-08 Online:2022-04-05 Published:2022-04-01
Contact: * tzcardiac@163.com

摘要/Abstract

摘要： 细胞外囊泡(EVs)是循环和体液中从细胞膜上分泌或脱落的小泡,在细胞间通讯起着关键作用。EVs可为房颤(AF)诊断、危险分层和评估提供生物标志物,并可作为药物的输送载体为房颤的靶向治疗提供可能。

关键词: 心房颤动, 细胞外囊泡, miRNA, 生物标志物, 靶向治疗

Abstract: Extra cellular vesicles (EVs) are small vesicles secreted or shed from cell membranes in circulating and body fluids and play a key role in intercellular communication. EVs can provide biomarkers for atrial fibrillation (AF) diagnosis, risk stratification and assessment and can be used as drug delivery vehicles for potential targeted therapies of AF.

Key words: atrial fibrillation, extracellular vesicles, miRNA, biomarkers, targeted therapy

中图分类号:

R541.7+5

何丹, 阮中宝. 细胞外囊泡在心房颤动发病中的作用[J]. 基础医学与临床, 2022, 42(4): 671-674.

HE Dan, RUAN Zhong-bao. Extracellular vesicles in the pathogenesis of atrial fibrillation[J]. Basic & Clinical Medicine, 2022, 42(4): 671-674.

参考文献

[1] Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge[J]. Int J Stroke, 2021, 16: 217-221.
[2] Zhang HX, Wu J, Wu JH, et al. Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice[J]. J Nanobiotechnology, 2019, 17: 29. doi: 10.1186/s12951-019-0461-7.
[3] Thulin Å, Lindbäck J, Granger CB, et al. Extracellular vesicles in atrial fibrillation and stroke[J]. Thromb Res, 2020, 193: 180-189.
[4] Théry C, Witwer KW, Aikawa E, et al.Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7: 1535750. doi: 10.1080/20013078.2018.1535750.
[5] Purushothaman A. Exosomes from cell culture-conditioned medium: isolation by ultracentrifugation and characterization[J]. Methods Mol Biol, 2019, 1952: 233-244.
[6] Xie J, Wu C. Ultrasensitive quantification of extracellular vesicles through dual signal amplification for the early diagnosis and prognosis of chronic obstructive pulmonary disease (COPD)[J]. Anal Methods, 2021. doi: 10.1039/d1ay01294k.
[7] Ruf J, Vairo D, Paganelli F, et al. Extracellular vesicles with ubiquitinated adenosine A2A receptor in plasma of patients with coronary artery disease[J]. J Cell Mol Med, 2019, 23: 6805-6811.
[8] Liu L, Zhang H, Mao H, et al. Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF)[J]. Artif Cells Nanomed Biotechnol, 2019, 47: 3976-3984.
[9] Xiao CT, Lai WJ, Zhu WA, et al. MicroRNA derived from circulating exosomes as noninvasive biomarkers for diagnosing renal cell carcinoma[J]. Onco Targets Ther, 2020, 13: 10765-10774.
[10] Mazzeo A, Beltramo E, Lopatina T, et al. Molecular and functional characterization of circulating extracellular vesicles from diabetic patients with and without retinopathy and healthy subjects[J]. Exp Eye Res, 2018, 176: 69-77.
[11] Mun D, Kim H, Kang JY, et al. Expression of miRNAs in circulating exosomes derived from patients with persistent atrial fibrillation[J]. FASEB J, 2019, 33: 5979-5989.
[12] Wang S, Min J, Yu Y, et al. Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm[J]. J Thorac Dis, 2019, 11: 4337-4348.
[13] Siwaponanan P, Keawvichit R, Udompunturak S, et al. Altered profile of circulating microparticles in nonvalvular atrial fibrillation[J]. Clin Cardiol, 2019, 42: 425-431.
[14] Mørk M, Andreasen JJ, Rasmussen LH, et al. Elevated blood plasma levels of tissue factor-bearing extracellular vesicles in patients with atrial fibrillation[J]. Thromb Res, 2019, 173: 141-150.
[15] Wang S, Li L, Hu X, et al. Effects of atrial fibrillation-derived exosome delivery of miR-107 to human umbilical vein endothelial cells[J]. DNA Cell Biol, 2021, 40: 568-579.
[16] Hou PP, Luo LJ, Chen HZ, et al. Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment[J]. Mol Cell, 2020, 78: 1192-1206.
[17] Wang Y, Jia L, Xie Y, et al. Involvement of macrophage-derived exosomes in abdominal aortic aneurysms development[J]. Atherosclerosis, 2019, 289: 64-72.
[18] Wang H, Song NP, Li JP, et al. The microvesicle/CD36 complex triggers a prothrombotic phenotype in patients with non-valvular atrial fibrillation[J]. J Cell Mol Med, 2020, 24: 7331-7340.
[19] Wang H, Yan HM, Tang MX, et al. Increased serum levels of microvesicles in nonvalvular atrial fibrillation determinated by ELISA using a specific monoclonal antibody AD-1[J]. Clin Chim Acta, 2010, 411: 1700-1704.
[20] Meng H, Kou J, Ma R, et al. Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation[J]. Mol Med Rep, 2017, 16: 8579-8588.
[21] Liu D, Kou X, Chen C, et al. Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors[J]. Cell Res, 2018, 28: 918-933.
[22] Tian Y, Zhu P, Liu S, et al. IL-4-polarized BV2 microglia cells promote angiogenesis by secreting exosomes[J]. Adv Clin Exp Med, 2019, 28: 421-430.
[23] Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids[J]. Cell Stem Cell, 2020, 27: 125-136.

细胞外囊泡在心房颤动发病中的作用

Extracellular vesicles in the pathogenesis of atrial fibrillation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[2]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.
[3]	李运龙, 李蕊, 张玉萍, 王瑞, 刘燕萍. 孕期锌缺乏及对妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 422-427.
[4]	郭爽, 李树仁, 赵美, 郝潇. 连接蛋白2和FGF23在房颤介导心肌病兔心房组织中的表达[J]. 基础医学与临床, 2024, 44(2): 199-203.
[5]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[6]	葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.
[7]	杨俊豪, 赵林. 恶性间皮瘤的靶向与免疫治疗[J]. 基础医学与临床, 2024, 44(10): 1342-1349.
[8]	方路, 刘睿奇, 梁鹏, 岑瑛. 外泌体miRNAs在器官纤维化中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1472-1476.
[9]	郑行健, 冉雪, 任梓月, 戴迟兵. 肠易激综合征生物标志物的研究进展[J]. 基础医学与临床, 2023, 43(3): 500-504.
[10]	姚刘旭, 李玉红, 蒋宗明. 外泌体lncRNA在结直肠癌液体活检中的研究进展[J]. 基础医学与临床, 2023, 43(2): 317-321.
[11]	缪昊真, 陶磊, 宋冰洁, 张奇军. 代谢重编程在心房颤动发生中作用的研究进展[J]. 基础医学与临床, 2023, 43(11): 1718-1722.
[12]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[13]	谢思安, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 刘思. VAV1是动脉粥样硬化预后的潜在靶点和生物标志物[J]. 基础医学与临床, 2022, 42(7): 1092-1098.
[14]	江辉, 张林. miRNAs可能通过调控MAPK通路参与心室间隔缺损[J]. 基础医学与临床, 2022, 42(4): 590-598.
[15]	谢聪聪, 王雪莹, 安卓, 姚胜杰, 马婧, 王树松. 胚胎发育生物标志物的研究进展[J]. 基础医学与临床, 2022, 42(1): 168-172.